Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)

Department of Hematology and Oncology, Georg August University Göttingen, Robert Koch Str. 40, 37075, Göttingen, Germany, .
Annals of Hematology (Impact Factor: 2.63). 04/2013; 92(4):433-42. DOI: 10.1007/s00277-013-1698-0
Source: PubMed

ABSTRACT Bacterial infections are the most common cause for treatment-related mortality in patients with neutropenia after chemotherapy. Here, we discuss the use of antibacterial prophylaxis against bacteria and Pneumocystis pneumonia (PCP) in neutropenic cancer patients and offer guidance towards the choice of drug. A literature search was performed to screen all articles published between September 2000 and January 2012 on antibiotic prophylaxis in neutropenic cancer patients. The authors assembled original reports and meta-analysis from the literature and drew conclusions, which were discussed and approved in a consensus conference of the Infectious Disease Working Party of the German Society of Hematology and Oncology (AGIHO). Antibacterial prophylaxis has led to a reduction of febrile events and infections. A significant reduction of overall mortality could only be shown in a meta-analysis. Fluoroquinolones are preferred for antibacterial and trimethoprim-sulfamethoxazole for PCP prophylaxis. Due to serious concerns about an increase of resistant pathogens, only patients at high risk of severe infections should be considered for antibiotic prophylaxis. Risk factors of individual patients and local resistance patterns must be taken into account. Risk factors, choice of drug for antibacterial and PCP prophylaxis and concerns regarding the use of prophylactic antibiotics are discussed in the review.

Download full-text


Available from: Silke Neumann, Sep 27, 2015
171 Reads
  • Annals of Hematology 04/2013; 92(11). DOI:10.1007/s00277-013-1743-z · 2.63 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Invasive infections caused by Aspergillus fumigatus as well as Pneumocystis pneumonia are serious and often lethal diseases in severely immunocompromised patients. Case report: We report on a rare case of a pulmonary coinfection of Pneumocystis jirovecii and Aspergillus fumigatus in a 59-year-old female patient with a history of astrocytoma treated with high doses of corticosteroids and a subsequent CD4 lymphocyte count of 30/µl. Conclusion: A heightened clinical awareness and a stringent and accurate diagnostic work-up encompassing diagnostic tools to detect even coincident fungal infections is crucial for sufficient and early antifungal treatment in immunocompromised patients with lung infiltrates.
    Onkologie 10/2013; 36(10):582-584. DOI:10.1159/000355168 · 0.86 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infections are the most common cause of morbidity and mortality in pediatric immunocompromised children. The emergence of pan-drug resistant bacteria is particularly concerning for these patients. The risk of infection can be reduced by educational rules, immunizing these patients and sometimes antibiotic prophylaxis. But the individual level of risk is very difficult to assess. Using antibiotics may lead to adverse effects such as allergic reactions, cross-reactions with other drugs, development of super-infections, pseudomembranous colitis and overall development of antibioticresistant bacterial strains. Recommendations for preventing infections in these patients exist for specific case such as inherited disorder or stem cell transplantation. In others cases it depends on physicians' habits: the increase of bacterial resistance could lead to reduce the prescriptions non evidence based and not included in official guidelines. Pneumococcal and meningococcal vaccinations might change guidelines and habits.
    Archives de Pédiatrie 11/2013; 20 Suppl 3:S94-8. DOI:10.1016/S0929-693X(13)71416-7 · 0.41 Impact Factor
Show more